U.S. regulators on Monday authorized emergency use of the first experimental antibody drug for COVID-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
Bryan Wood reports.
Mayo Clinic experimental treatment for COVID-19 patients
KIMT
The treatment is a one hour infusion that's done outpatient and you have to be monitored for an hour afterwards.
